OLYSIO® sales during the fourth quarter 2014
Stockholm, Sweden — Medivir AB (OMX: MVIR) announces that the global fourth quarter net sales of OLYSIO® (simeprevir) amounted to 321 MUSD, of which 256 MUSD were sales in the USA.
Medivir’s royalties based on sales for the fourth quarter are calculated from the highest royalty tier and currency conversion from USD to Euro is based on the YTD exchange rate.
The royalty amounted to 220 MSEK (23.1 MEUR).
|OLYSIO® global net sales||Sales in MUSD|
|Market||Q4 2014||Q3 2014||Q2 2014||Q1 2014|
|Total global net sales MUSD||321||796||831||354|
Medivir will publish its Financial Statement on February 27, 2015 at 8.30 CET followed by a conference call for investors, analysts and the media at 14.00 CET. More information about the conference call/webcast will be posted at www.medivir.com .
For more information please contact:
Rein Piir, EVP Corporate Affairs & IR, mobile: +46 708 537 292
Medivir is required under the Securities Markets Act to make the information in this press release public.
The information was submitted for publication at 13.55 CET on 20 January 2015.
About Simeprevir (OLYSIO®)
Simeprevir is an NS3/4A protease inhibitor jointly developed by Janssen Sciences Ireland UC and Medivir AB and has been approved for the treatment of chronic hepatitis C infection as a component of a combination antiviral treatment regimen in 36 countries worldwide.
In November 2014 simeprevir was approved, in combination with sofosbuvir as an all-oral, interferon- and ribavirin-free treatment option for genotype 1 chronic hepatitis C (CHC) infection in adult patients as part of a combination antiviral treatment regimen.
Simeprevir efficacy has been established in HCV genotype 1 and HCV genotype 4 infected patients with compensated liver disease, including cirrhosis. Janssen is responsible for the global clinical development of simeprevir and has exclusive, worldwide marketing rights, except in the Nordic countries. Medivir AB retains marketing rights for simeprevir in these countries under the marketing authorization held by Janssen-Cilag International NV.
Simeprevir is marketed under the trade name OLYSIO® in the U.S., European Union, Mexico, Australia and Saudi Arabia, Sovriad® in Japan and Russia and Galexos™ in Canada.
Medivir is an emerging and profitable research‐based pharmaceutical company with an established marketing and sales organisation in the Nordic region with a broad portfolio of prescription pharmaceuticals.
Medivir receives royalties from Johnson & Johnson on the global sales of the hepatitis C pharmaceutical, OLYSIO®. In addition, revenues for sales of OLYSIO in the Nordic region are generated through the company’s own sales and marketing organisation. Medivir’s research and development portfolio of pharmaceuticals is based on the company’s expertise within protease inhibitor design and nucleoside/nucleotide science. The company’s research and development focus is within infectious diseases and oncology and the on-going clinical projects in osteoarthritis and neuropathic pain.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.